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Three founder mutations in BRCA1 and BRCA2 account for about
10% of breast cancer occurring in Ashkenazi Jewish women diag-
nosed at 65 years of age or less (Karp et al, 1997). Other genes,
such as ATM and RASH may play a role in breast cancer suscepti-
bility, but their contribution to breast cancer incidence is presently
unknown. The I1307K polymorphism in APC has recently been
found to be associated with an increased risk of colorectal cancer:
the odds ratio (OR) of colorectal cancer in association with this
polymorphism was 1.78 for all cases and 2.86 for those diagnosed
at under age 66 (Laken et al, 1997). Interestingly, in four of the
eight pedigrees illustrated in that paper, possible I1307K-carrying
women had been diagnosed with breast (three kindreds) or ovarian
cancer (one kindred). We and others have shown that the I1307K
polymorphism is over-represented in Ashkenazi Jewish women
with breast cancer, compared with ethnically-matched controls
(OR = 1.5, P = 0.003) (Redston et al, 1998). To further understand
the way in which the I1307K allele might increase the risk of
breast cancer, we used a historical cohort approach to compare the
clinicopathological features of breast cancers occurring in those
carrying the I1307K polymorphism in APC, with those seen in
non-carriers. The effect of the I1307K allele on breast cancer
survival was determined.
MATERIALS AND METHODS
Cases
Study subjects were identified in the medical records department
of the Sir Mortimer B Davis Jewish-General Hospital (SMBD-
JGH) and included women who self-reported as being Ashkenazi
Jewish by birth and who were diagnosed with invasive breast
cancer below 65 years of age between 1 January 1986 and 1
November 1995. Two hundred and nine breast cancer blocks from
eligible women were identified. All but nine of these samples were
used in the primary study (Redston et al, 1998). These samples
were rendered anonymous after clinicopathological information
was obtained from chart review, and therefore we have no family
history available for any of these women. All pathological and
molecular analyses of the samples were carried out blinded. The
study was approved by the Research Ethics Committee of the
SMBD-JGH. Specimens were reviewed by one pathologist (LB).
Histological tumour type, grade (1–3) and axillary lymph node
status (positive or negative for breast cancer metastases, with the
number of positive lymph nodes recorded) was determined by
specimen and chart review. The specimens were then coded and
DNA was extracted from the paraffin wax-embedded blocks using
standard techniques. We used tumour tissue as a source of DNA,
and it is possible that I1307K polymorphisms detected could
represent somatic mutations. However, loss of heterozygosity
(LOH) is not common on 5q in breast cancer (Thompson et al,
1993; Devilee and Cornelisse, 1994; Medeiros et al, 1994) and no
shortened forms of the APC protein were observed in cell lines
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from patients with breast cancer (Smith et al, 1993). Both these
observations suggest that somatic APC mutations are rare.
Allele-specific oligonucleotide (ASO) hybridization for
I1307K APC polymorphism
Genomic DNA from the 210 cases was amplified for polymerase
chain reaction (PCR) using primers published previously (Laken
et al, 1997). The PCR products were dot-blotted onto nylon filters
and hybridized with wild- and mutant type probes at codon 1307.
A positive control sample was included on all filters.
Sequence analysis
Genomic DNA PCR products from samples that were positive by
ASO were purified from low-melting agarose gels. Sequences were
determined by the dideoxynucleotide-termination method with
T7 sequenase Version 2.0 (Amersham Life Science). A positive
control was included in each sequencing run. All ASO-positive
samples and three ASO-negative samples were sequenced. In all
cases, the results were concordant. All 24 positive cases were
available for microdissection. Direct sequencing of both malignant
and, where possible (n = 17) non-malignant regions of the available
paraffin-embedded materials was carried out.
Single-strand conformation analysis
All breast cancer tumours were reviewed by one pathologist
(LRB). Specimens where more than 20% of the cells on each
section were malignant were chosen for PCR analysis. We chose
this figure because dilution experiments demonstrated that we
could not detect the I1307K polymorphisms in specimens where
less than 20% of the available DNA was derived from a positive
control sample. Undissected breast cancer specimens were
prepared for PCR. After PCR using published primers (Laken
et al, 1997), 1 ml of each reaction mixture was transferred into 6 ml
dimethyl sulphoxide (DMSO), loading buffer (30% DMSO, 1 mM
EDTA, 0.05% bromophenol blue, 0.05% Xylene cyanol). The
samples were heated at 95°C for 5 min and then quickly cooled on
ice. Five-microlitres of each mixture was loaded on a 10% non-
denaturing polyacrylamide gel (ratio of acrylamide/bisacrylamide
50:1) containing 50 mM Tris–borate (pH 8.3) and 10% glycerol.
Electrophoresis was performed using a mini single-strand confor-
mation analysis (SSCA)-gel apparatus at 300 V for 3–4 h at 4°C.
After electrophoresis, gels were silver-stained with Silver Stained
Plus Kit (Bio-Rad) and dried. The fragment analysed was 115 base
pairs long: the A®T polymorphism is present 43 nucleotides
downstream from the 3¢ end of the upstream primer.
Oestrogen receptor status
Where available, the conventional radioimmunoassays (RIA) were
used to determine oestrogen and progesterone nuclear protein
status. These assays were performed at the SMBD-JGH at the time
of initial breast cancer surgery using established techniques. A
positive oestrogen receptor (ER) or progesterone receptor (PR)
score was taken as >10 fmol mg–1 protein. In some cases, no
record of the RIA could be located, or the diagnostic sample was
too small to be studied by RIA, and therefore the ER and PR
status was determined by immunohistochemistry using the
streptavidin–biotin peroxidase complex methodology. For ER and
PR nuclear protein analyses, antibodies 6F11 and 1A6 respectively
(Ventana), were used pre-diluted. A positive score was based on
>10% cells showing clear, intense nuclear staining, with no
background cytoplasmic staining.
P53 immunohistochemistry
P53 protein accumulation was detected using a standard strepta-
vidin–biotin peroxidase immunohistochemical technique. Anti-
P53 (DO-7) monoclonal antibody (Dakopatts) was used at a
dilution of 1/50. Four-micron sections were prepared from
paraffin-embedded tumour material, and deparaffinized using
toluene. Sections were washed in absolute ethanol for 3 min, with
two changes, washed in 95% ethanol for 3 min and immersed in
tap water for 5 min. Sections were rinsed with distilled water and
subsequently immersed in 0.01 M citrate buffer at pH 6.0.
Microwave antigen retrieval was performed (5 min ´ 2) with
distilled water immersion. Slides were processed with a Ventana
automated system, including the following reagents: hydrogen
peroxide (inhibitor), biotinylated Ig, streptavidin HRPO,
DAB–hydrogen peroxide copper and haematoxylin. P53 nuclear
reactivity was assessed quantitatively as a percentage of nuclei
with positive staining among tumour cells and qualitatively in
terms of range of staining intensity (+, slight; ++, moderate; or
+++, strong). Positivity for P53 accumulation implied 10% of
tumour cell nuclei showed immunoreactivity.
Statistical analysis
Methods
For the continuous descriptive analysis, we used the t-test and
the non-parametric Wilcoxon test. For the discrete descriptive
analysis, we used Fisher’s exact test to calculate the P-values and
the odds ratio for the corresponding measure of association. The
variables were defined as: age (continuous: 28–50, 50–64), tumour
size (≤ 2 cm vs > 2 cm), grade (1 vs 2 vs 3), nodal status
(0 involved nodes vs 1 or more involved nodes), ER receptor
status (negative vs positive) and P53 status (positive vs negative).
Confidence intervals were exact binomial probabilities.
Kaplan–Meier plots were drawn for breast cancer specific
mortality. The log-rank test was used to assess the significance of
differences in outcome observed.
Power
For a = 0.05 and 1-b = 0.80, in this study we could detect ORs
greater or equal to 3.3 (tumour size dichotomized), 3.2 (nuclear
grade 1 and 2 vs 3), 3.4 (lymph node) and 3.4 (P53) for the
association between I1307K positivity and the above-mentioned
variables. For the cohort study, we have an 80% power to detect a
29% difference in survival between the carriers and non-carriers of
I1307K, with a at 0.05.
RESULTS
In this series of 209 Montreal Ashkenazi Jewish women with
breast cancer diagnosed at less than 65 years of age, we found that
24 women (11.5%, 95% confidence interval (CI) 7.5–16.6) were
carriers of the I1307K APC polymorphism. No somatic mutations
around the I1307K locus were identified by direct mutation
analysis of any of the 24 microdissected cases that carried the
I1307K polymorphism. In 17/24 cases which were positive for the852 ZQ Yuan et al
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I1307K polymorphism, non-malignant tissue was also available.
In all cases, the I1307K polymorphism was also present in these
cells, thus confirming that the variant observed was present in the
germline. Because of data suggesting that the mutated allele might
be a site for further somatic mutations, we were concerned that
these mutations might have destroyed the ASO-specific sequence,
rendering it unavailable for hybridization. However, no alterations
were observed in 158 undissected cases that were wild-type by
ASO for whom we had remaining tissue available.
We stratified the data by relevant clinicopathological variables
such as age at diagnosis, grade, tumour size, axillary nodal status,
ER status and P53 immunoreactivity. There was a higher
frequency of the I1307K polymorphism in higher grade breast
cancers, but the trend was not significant (P = 0.074) (Table 1).
Because we observed this trend, we stratified the data by BRCA
mutation status, to determine whether this relationship was
confounded by an underlying association between BRCA mutation
status and grade. In fact, there was no association between grade
and I1307K status in BRCA mutation carriers (overall P = 0.62,
data not shown) and in non-BRCA carriers, the OR for high grade
versus low grade was 1.60 (95% CI 0.26–9.9, P = 0.68). The only
significant difference in any group was seen for non-BRCA
mutation carriers, where I1307K carriers were significantly more
likely to be grade 2 rather than grade 1 (OR 5.0, 95% CI 1.23–21,
P = 0.04) but this was only of borderline significance. There was
no association between the histological type of the breast cancer
and the presence of the I1307K polymorphism, with 75.8% of
APC wild-type and 70.8% of I1307K carriers having the common
ductal type of invasive breast cancer. While it is clear that this
study has limited power (~40%) to detect ORs of 2 or less, there is
no dramatic association between the I1307K polymorphism and
any variable we studied. This is in contrast with the situation for
BRCA1, where using a subset of the cases reported here, we have
shown that BRCA1-positive status is highly correlated with high-
grade, ER-negative and P53-positive breast cancers (Karp et al,
1997; Foulkes et al, manuscript submitted).
We then studied the effect of the I1307K polymorphism. Not
surprisingly, given the absence of any clear association between
this polymorphism and clinicopathological variables, breast cancer
specific 5-year and 8-year survival did not significantly differ
between the I1307K carriers and non-carriers (Figure 1).
DISCUSSION
A mis-sense mutation in APC was identified in a 39-year-old
Ashkenazi Jewish man with eight colorectal polyps (Laken et al,
1997). His father had colorectal polyps and his paternal grand-
mother had both colorectal cancer, diagnosed at age 60 and
ovarian cancer at age 72. There was no evidence of FAP. The poly-
morphism seems to predispose to cancer not as a direct effect on
the protein, but by rendering this region of APC hypermutable.
The polymorphism was found in 47 of 766 (6.1%) Ashkenazi
Jewish individuals who were not known to have colorectal cancer,
but for whom family history was unavailable. It was also detected
in 22 of 211 (10.4%) Ashkenazi Jewish individuals with colorectal
cancer for whom family history was available, 172 of which were
unselected for family history. Other cancers seen in these families
included breast, ovarian, prostate, uterine and throat cancer. Three
of the eight illustrated kindreds had at least one case of breast
cancer.
In contrast to this positive finding, in 264 individuals from 158
Ashkenazi Jewish breast and breast/ovarian cancer kindreds there
was no excess of colorectal cancer in either those who carried the
I1307K polymorphism (n = 12) or their relatives (Petrukhin et al,
1997). Although the nature of that study precluded the authors
from drawing any conclusions regarding I1307K and breast cancer
risk in the Ashkenazim, the frequency of the I130K polymorphism
was only 4.5% overall (12 positive individuals (11 families) from
264 individuals (158 families)). Therefore it is difficult to argue
that the I1307K polymorphism predisposes to breast cancer from
their study, as the 4.5% frequency is lower than seen in the controls
in the Laken et al (1997) study.
In a large collaborative study an increased prevalence of the
I1307K polymorphism in Ashkenazi Jewish women with breast
cancer compared with controls was observed (OR = 1.5, 95% CI
1.1–2.0, P = 0.003) (Redston et al, 1998). This effect was mainly,
if not entirely, limited to women who also carried BRCA muta-
tions. In this present study, we analysed the Montreal cases from
that publication to determine the relationship between the presence
of the I1307K polymorphism and other clinicopathological
variables that were available to us (Table 1). The absence of any
significant associations, and the fact that we observed no somatic
mutations by direct sequencing or by SSCA, suggests that if the
Table 1 The I1307K polymorphism: comparison with clinicopathological characteristics of cases
Variable I1307K/+ +/+ Odds ratio 95% confidence P-value
(wild-type) interval
Age at diagnosis (years) 28–50 8 76
50–65 16 109 1.39 0.57–3.42 0.52
Tumour size (cm) <2 14 108
2–8 10 77 1.00 0.42–2.38 0.99
Nuclear grade Low (1) 2 52 1.00
Moderate (2) 13 68 4.97 1.21–20.4 0.027
High (3) 9 65 3.60 0.81–16.1 0.12a
Axillary lymph nodesb Absent 15 106
Present 8 67 0.84 0.34–2.10 0.82
Oestrogen receptorsc Absent 4 55
Present 20 129 2.13 0.71–6.41 0.23
p53 immunohistochemistryd Absent 18 136
Present 6 41 1.11 0.41–3.0 0.80
aOverall P-value: 0.074; b12 wild-type and 1 I1307K carriers did not have an axillary dissection; cone wild-type case was not studied for ER status; deight wild-
type cases were not studied by immunohistochemistry.I1307K polymorphism and breast cancer survival 853
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I1307K polymorphism does confer an increased risk of breast
cancer, it is through a novel mechanism. Genes that confer
increased risk of cancer often are associated with a particular
phenotype. For example, BRCA1 mutation carriers develop breast
cancers at a younger than average age and the tumours that occur
are more likely to be high-grade and ER-negative, even taking into
account that they occur in younger women (Karp et al, 1997).
Likewise, HNPCC-associated colorectal cancers are more likely to
be mucinous and situated in the right colon than their sporadic
counterparts (Lynch et al, 1993). The I1307K polymorphism has
not been associated with any particular colorectal phenotype, other
than a possible earlier age of onset. In Laken et al (1997) there
were no grade or stage data provided for the colorectal cancers.
Gryfe et al (1999) studied 476 Ashkenazi Jewish patients with
colorectal cancer. I1307K carriers had more adenomas and cancers
per person than non-carriers, and were diagnosed at a slightly
younger age (P 0.03). The data in this series of 209 breast cancers
indicate that there are no special features of the breast cancers that
occur in I1307K carriers.
There have been several 5q LOH studies in breast cancer. The
two studies specifically studying markers within, or adjacent to
APC found modest levels of LOH, in the range 11–28%
(Thompson et al, 1993; Medeiros et al, 1994). Allelotype studies
including at least one marker on 5q have failed to reveal high
levels of LOH (Devilee and Cornelisse, 1994). There are no
reported studies of APC mutation testing in women with breast
cancer, probably because breast cancer is not a feature of familial
adenomatous polyposis (FAP). Nevertheless, the low level of LOH
on 5q would support the viewpoint that APC is not commonly a
target for mutations in sporadic breast cancer. The absence of trun-
cated APC proteins in seven breast cancer cell lines also indicates
that truncating APC mutations are unlikely to be common (Smith
et al, 1993). However, animal models of FAP have provided
another perspective. Min is a mutant allele of the murine Apc
locus, and is a murine model for human FAP. Interestingly, B6
Min/+ females develop breast tumours, albeit at a low rate (5%),
which increases in mice exposed to ethylnitrosurea (Moser et al,
1995). A complicating factor is that the Min allele encodes a stop
at codon 850, resulting in a truncated protein, like most APC muta-
tions that cause FAP. In contrast, the I1307K polymorphism does
not result in a truncated protein. So it is uncertain if there is any
biological connection between the breast cancers we observed in
I1307K polymorphism carriers in this study and breast tumours in
Min mice.
LOH on 5q is common in colorectal cancer, but it is not clear
from Laken et al (1997) whether LOH was present in the 23
colorectal cancers from the I1307K-positive individuals that were
analysed. In 11, the I1307K allele had suffered somatic mutation
centred on codon 1307, but it is not stated whether LOH of the
wild-type allele had occurred in these or in the 12 I1307K-positive
samples that did not have somatic mutations around this site
(Laken et al, 1997). In this study, we sequenced 24 microdissected
tumour samples that carried the I1307K polymorphism. The muta-
tions appeared to be germline in origin, with no evidence of
somatic instability. In addition, to rule out the possibility that
somatic mutations might be present that might destroy the ASO
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Figure 1 Kaplan–Meier survival curves with regard to survival until death from breast cancer are shown for heterozygotes for the 1307K polymorphism (—)
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site (and thus be recorded as false negative by ASOH), we
analysed 158 APC wild-type cases by SSCA but no variants were
observed (data not shown).
Overall, this study suggests that the I1307K APC polymorphism
is not associated with any particular clinicopathological features of
breast cancer and, in particular, does not affect survival. The
significance of this variant for breast cancer risk in the
Ashkenazim remains to be fully determined.
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